Connor, Clark & Lunn Investment Management Ltd. Apellis Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 118,724 shares of APLS stock, worth $3.21 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
118,724
Previous 131,895
9.99%
Holding current value
$3.21 Million
Previous $2.88 Million
28.74%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding APLS
# of Institutions
299Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$331 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$322 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$275 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$264 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$243 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.97B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...